Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting
28 Marzo 2024 - 2:00PM
Business Wire
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics
for precision oncology, announced today that a podium talk and
multiple abstracts featuring data for the company’s NeXT Personal®
whole genome-based, tumor-informed assay for ultra-sensitive ctDNA
detection will be presented at the American Association for Cancer
Research (AACR) Annual Meeting, taking place in San Diego,
California, April 5-10, 2024.
“Personalis is excited to present data showing our
ultra-sensitive MRD test, NeXT Personal, has the potential to find
recurrent cancer earlier and monitor response in late-stage cancer
patients receiving immunotherapy,” said Dr. Richard Chen, Chief
Medical Officer and Executive Vice President, R&D at
Personalis.
Personalis will be sharing progress with collaborative research
findings as well as the latest clinical results related to NeXT
Personal. Highlights include:
- Mini-symposium (Liquid Biopsy): Ultra-sensitive ctDNA
detection predicts response to immune checkpoint inhibition in
advanced melanoma patients
- Speaker: Dr. Christoffer Gebhardt
- Date & Time: Tuesday, April 9, 2:55 PM - 3:10 PM
- Location: Room 6 CF - Upper Level - Convention Center
ctDNA dynamics detected with NeXT Personal
were predictive of patient response and outcomes in melanoma
patients receiving immunotherapy; over a third of ctDNA detections
were in the ultra-sensitive range (<100 PPM) in advanced
melanoma patients.
- Abstract Title: Detection of circulating tumor DNA predicts
survival in advanced HCC patients treated with personalized
therapeutic DNA cancer vaccine in combination with
immune-checkpoint blockade
- Session Date & Time: Sunday, Apr 7, 2024 1:30 PM - 5:00
PM
- Location: Poster Section 40, Number 17
- Abstract Number: 976
Changes in ctDNA levels detected with NeXT
Personal predicted therapy response and overall survival in
late-stage hepatocellular carcinoma patients treated with a
personalized cancer vaccine.
- Abstract Title: Analytic validation of an ultra-sensitive
tumor-informed circulating tumor DNA assay based on whole genome
sequencing
- Session Date & Time: Tuesday, Apr 9, 2024 9:00 AM - 12:30
PM
- Location: Poster Section 40, Number 21
- Abstract Number: 5034
Analytical validation of NeXT Personal
demonstrated ultra-sensitivity down to 1 PPM of ctDNA and high
specificity, reinforcing the potential to detect recurrent cancer
earlier.
- Abstract Title: Detection of MRD assessment with the
Personalis NeXT Personal assay using MATRIX plasma-in-plasma
contrived samples
- Session Date & Time: Tuesday, Apr 9, 2024 1:30 PM - 5:00
PM
- Location: Poster Section 31, Number 20
- Abstract Number: 6094
Biopharma partner blinded study showed NeXT
Personal’s ability to detect ultra-low levels of ctDNA.
About Personalis, Inc.
At Personalis, we are transforming the active management of
cancer through breakthrough personalized testing. We aim to drive a
new paradigm for cancer management, guiding care from biopsy
through the life of the patient. Our highly sensitive assays
combine tumor-and-normal profiling with proprietary algorithms to
deliver advanced insights even as cancer evolves over time. Our
products are designed to detect minimal residual disease (MRD) and
recurrence at the earliest time points, enable the selection of
targeted therapies based on ultra-comprehensive genomic profiling,
and enhance biomarker strategy for drug development. Personalis is
based in Fremont, California. To learn more, visit
www.personalis.com and connect with us on LinkedIn and X
(Twitter).
Forward-Looking Statements
All statements in this press release that are not historical are
“forward-looking statements” within the meaning of U.S. securities
laws, including statements relating to attributes or advantages of
the NeXT Personal assay, the potential for NeXT Personal to detect
recurrent cancer earlier or monitor response in cancer patients
receiving immunotherapy, the ability of NeXT Personal to detect
ultra-low levels of ctDNA with high specificity or to predict
patient therapy response or outcomes, or other future events. Such
forward-looking statements involve risks and uncertainties that
could cause actual results to differ materially from any
anticipated results or expectations expressed or implied by such
statements. Factors that could materially affect actual results can
be found in Personalis’ filings with the U.S. Securities and
Exchange Commission, including Personalis’ most recent reports on
Forms 8-K, 10-K and 10-Q, and include those listed under the
caption “Risk Factors.” Personalis disclaims any obligation to
update such forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240328348049/en/
Investors: Caroline Corner investors@personalis.com
415-202-5678
Media: pr@personalis.com
Grafico Azioni Personalis (NASDAQ:PSNL)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Personalis (NASDAQ:PSNL)
Storico
Da Dic 2023 a Dic 2024